FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)									1				
1. Name and Address of Reporting Person * Benton Susan				2. Issuer Name and Ticker or Trading Symbol Ocuphire Pharma, Inc. [OCUP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O OCUPHIRE PHARMA, INC., 37000 GRAND RIVER AVE, SUITE 120				3. Date of Earliest Transaction (Month/Day/Year) 07/01/2022						Office	r (give title belo	ow)	Other (specify	pelow)	
(Street) FARMINGTON HILLS, MI 48335				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City	')	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	(Instr. 8)		(4	A) or D	Securities Acquired a) or Disposed of (D astr. 3, 4 and 5)				ollowing Ow s) For Dir	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
					Со	de	V A	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock 07/01/2022		07/01/2022		A	1	6	5,335	A	<u>(1)</u>	38,790			D		
Common Stock 0		07/01/2022		A	A	1	2,376	A	<u>(2)</u>	51,166		D			
				Derivative Securi		quire	contain the for ed, Disp	ned in rm disp oosed of	this for plays a o	m are curre eficia	e not requently valid	OMB conf	spond unle	ss	1474 (9-02)
Derivative Conversion Date		3. Transaction Date (Month/Day/	n 3A. Deemed Execution Da any	e.g., puts, calls, w 4. Transaction Code Year) (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date expiration Date Expiration Date Expiration Date Expiration Date Exercisable Date		7. T Am Und Sec (Ins 4)	Amount or Number of		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Owners Form of Derivat Security Direct (or Indir	Beneficia Ownersh (Instr. 4)	
				Code V	(A)	(D)					Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Benton Susan C/O OCUPHIRE PHARMA, INC. 37000 GRAND RIVER AVE, SUITE 120 FARMINGTON HILLS, MI 48335	X					

Signatures

/s/ Emily J. Johns, by Power of Attorney	07/06/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person was granted shares of common stock in lieu of cash for board services for the second quarter of 2022. The number of shares of common stock was (1) determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was \$1.92 per share, the closing price of the common stock on June 30, 2022.
- The Reporting Person was granted shares of common stock in lieu of cash for board services for the second half of 2022. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was \$2.02 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to July 1, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.